BioAxone receives fast track grant for Rho Kinase 2 inhibitor to improve outcomes in chronic SCI

CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone BioSciences, Inc. announced today the receipt of a Fast-Track grant (R44 NS110290-01) from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, as part of the agency’s Small Business Innovation Research (SBIR) Program. The grant provides funding for milestone-driven research to assess the potential of BA-1049, a Rho Kinase 2 (ROCK2) inhibitor in BioAxone’s pipeline, to improve recovery in chronic spinal cord injury. BA-1049 is a first-in-class ROCK2-selective inhibitor that has shown promising safety and efficacy in multiple preclinical models of neurovascular disease.

See the full article at Business Wire